Should You Buy AstraZeneca PLC Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, AstraZeneca PLC (AZN) ranks in the top tier of our coverage universe with a Quality of Company score of 9.3/10. Trading at a market price of $161.85, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 6 of 11 CirclFi valuation models project upside for AstraZeneca PLC (AZN) at $161.85 — the model consensus leans bullish, with a Quality Score of 9.3/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for AstraZeneca PLC (AZN) in 2026?
What Is the Bull Case vs the Bear Case for AstraZeneca PLC (AZN)?
| Bull case — $411.20 target (+154.1%) | Bear case — $73.84 target (-54.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, AstraZeneca PLC's quality score of 9.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $73.84 (-54.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $161.85 and the median fair value of $178.36 implies +10.2% upside potential. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +208.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $411.20 (+154.1%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios. | Industry headwind: clinical trial failure represents a meaningful risk for AstraZeneca PLC and its Drug Manufacturers - General peers. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for AstraZeneca PLC's revenue and margin trajectory in the Drug Manufacturers - General space. | |
| The company's $251.0B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does AZN Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: NVO · JNJ · LLY · GSK · MRK · BMY · BIIB · GRFS · NVS · GILD
Which Other Stocks Score Like AZN on Quality?
Closest companies to AZN’s Quality of Company score of 9.3/10, across all industries.
- AMP — Ameriprise Financial, Inc. (QOC 9.3) · analysis
- PH — Parker-Hannifin Corporation (QOC 9.3) · analysis
- SHOP — Shopify Inc. (QOC 9.3) · analysis
- NEM — Newmont Corporation (QOC 9.3) · analysis
- MEDP — Medpace Holdings, Inc. (QOC 9.3) · analysis
- BMI — Badger Meter, Inc. (QOC 9.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is AstraZeneca PLC (AZN) Worth Buying in 2026?
Our models don't have a clear verdict on AstraZeneca PLC. At $161.85 vs. $178.36 median fair value, the median upside of +10.2% masks significant model disagreement (+208.4% spread). With quality at 9.3/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. AstraZeneca PLC's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About AZN Stock?
Should I buy AZN stock right now?
Based on CirclFi's multi-model analysis, 6 of 11 models see upside for AZN at $161.85. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 9.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in AstraZeneca PLC?
Key risks include: wide model disagreement (457% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does AZN compare to its competitors?
Among Drug Manufacturers - General peers, AZN holds a Quality Score of 9.3/10. Comparable companies include NVO (QOC 9.3), JNJ (QOC 9.0), LLY (QOC 9.4). The relative ranking helps investors identify whether AZN offers better fundamental quality than alternatives in the same sector.
Is AZN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AZN's Quality Score of 9.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy AZN at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $73.84 to $411.20. At $161.85, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for AZN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad